Literature DB >> 24583767

GLP-1-based strategies: a physiological analysis of differential mode of action.

Rémy Burcelin1, Pierre Gourdy, Stéphane Dalle.   

Abstract

DPP4 inhibitors and GLP-1 receptor agonists used in incretin-based strategies treat Type 2 diabetes with different modes of action. The pharmacological blood GLP-1R agonist concentration targets pancreatic and some extrapancreatic GLP-1R, whereas DPP4i favors the physiological activation of the gut-brain-periphery axis that could allow clinicians to adapt the management of Type 2 diabetes, according to the patient's pathophysiological characteristics.

Entities:  

Mesh：

Substances：

Year:  2014        PMID： 24583767     DOI： 10.1152/physiol.00009.2013

Source DB:  PubMed          Journal:  Physiology (Bethesda)        ISSN： 1548-9221


  10 in total

Review 1.  Pleiotropic effects of the dipeptidylpeptidase-4 inhibitors on the cardiovascular system.

Authors:  Annayya R Aroor; James R Sowers; Guanghong Jia; Vincent G DeMarco
Journal:  Am J Physiol Heart Circ Physiol       Date:  2014-08-15       Impact factor: 4.733

2.  A Novel Bacterium, Butyricimonas virosa, Preventing HFD-Induced Diabetes and Metabolic Disorders in Mice via GLP-1 Receptor.

Authors:  Heetae Lee; Jinho An; Jiyeon Kim; Dohyun Choi; Youngcheon Song; Chong-Kil Lee; Hyunseok Kong; Sang Bum Kim; Kyungjae Kim
Journal:  Front Microbiol       Date:  2022-05-17       Impact factor: 6.064

Review 3.  Therapeutic potential of α7 nicotinic acetylcholine receptor agonists to combat obesity, diabetes, and inflammation.

Authors:  Han Xie; Natesh Yepuri; Qinghe Meng; Ravi Dhawan; Colin A Leech; Oleg G Chepurny; George G Holz; Robert N Cooney
Journal:  Rev Endocr Metab Disord       Date:  2020-08-26       Impact factor: 6.514

4.  Ghrelin: a new incretin enhancer therapy?

Authors:  Vincent G DeMarco; James R Sowers
Journal:  Diabetes       Date:  2015-05       Impact factor: 9.461

Review 5.  Surgical treatment of nonalcoholic fatty liver disease in severely obese patients.

Authors:  Steven J Vander Naalt; Juan P Gurria; AiXuan L Holterman
Journal:  Hepat Med       Date:  2014-10-29

Review 6.  Practical strategies for improving outcomes in T2DM: The potential role of pioglitazone and DPP4 inhibitors.

Authors:  Stefano Del Prato; Robert Chilton
Journal:  Diabetes Obes Metab       Date:  2017-12-21       Impact factor: 6.577

7.  Role of adipose tissue GLP-1R expression in metabolic improvement after bariatric surgery in patients with type 2 diabetes.

Authors:  Miriam Ejarque; Fernando Guerrero-Pérez; Nuria de la Morena; Anna Casajoana; Nuria Virgili; Rafael López-Urdiales; Elsa Maymó-Masip; Jordi Pujol Gebelli; Amador Garcia Ruiz de Gordejuela; Manuel Perez-Maraver; Silvia Pellitero; Sonia Fernández-Veledo; Joan Vendrell; Nuria Vilarrasa
Journal:  Sci Rep       Date:  2019-04-18       Impact factor: 4.379

Review 8.  Anti-Inflammatory Effects of GLP-1 Receptor Activation in the Brain in Neurodegenerative Diseases.

Authors:  Yolanda Diz-Chaves; Zainab Mastoor; Carlos Spuch; Lucas C González-Matías; Federico Mallo
Journal:  Int J Mol Sci       Date:  2022-08-24       Impact factor: 6.208

Review 9.  Exenatide once-weekly injection for the treatment of type 2 diabetes in Chinese patients: current perspectives.

Authors:  Wuquan Deng; Sheng Qiu; Gangyi Yang; Bing Chen
Journal:  Ther Clin Risk Manag       Date:  2015-08-10       Impact factor: 2.423

10.  Effects of Incretin-Based Therapies on Neuro-Cardiovascular Dynamic Changes Induced by High Fat Diet in Rats.

Authors:  Silvio Rodrigues Marques-Neto; Raquel Carvalho Castiglione; Aiza Pontes; Dahienne Ferreira Oliveira; Emanuelle Baptista Ferraz; José Hamilton Matheus Nascimento; Eliete Bouskela
Journal:  PLoS One       Date:  2016-02-01       Impact factor: 3.240
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.